Cargando…
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therape...
Autores principales: | Long, Lu, Ormiston, Mark L., Yang, Xudong, Southwood, Mark, Gräf, Stefan, Machado, Rajiv D., Mueller, Matthias, Kinzel, Bernd, Yung, Lai Ming, Wilkinson, Janine M., Moore, Stephen D., Drake, Kylie M., Aldred, Micheala A., Yu, Paul, Upton, Paul D., Morrell, Nicholas W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496295/ https://www.ncbi.nlm.nih.gov/pubmed/26076038 http://dx.doi.org/10.1038/nm.3877 |
Ejemplares similares
-
The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations
por: Dunmore, Benjamin J., et al.
Publicado: (2013) -
The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension
por: Ormiston, Mark L., et al.
Publicado: (2015) -
Targeting translational read-through of premature termination
mutations in BMPR2 with PTC124 for pulmonary arterial
hypertension
por: Long, Lu, et al.
Publicado: (2020) -
Reduced circulating BMP9 and pBMP10 in hospitalized COVID‐19 patients
por: Dunmore, Benjamin J., et al.
Publicado: (2023) -
Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling
por: Theilmann, Anne L., et al.
Publicado: (2020)